Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Equity (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Return on Equity for 9 consecutive years, with 1.37% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 1446.0% to 1.37% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.37%, a 1446.0% increase, with the full-year FY2025 number at 2.44%, up 28.0% from a year prior.
  • Return on Equity was 1.37% for Q4 2025 at Rhythm Pharmaceuticals, up from 2.81% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.43% in Q2 2021 to a low of 52.03% in Q2 2025.
  • A 5-year average of 5.33% and a median of 0.94% in 2023 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 1446bps in 2025; the steepest drop was -4689bps in 2025.
  • Rhythm Pharmaceuticals' Return on Equity stood at 0.59% in 2021, then dropped by -13bps to 0.66% in 2022, then plummeted by -52bps to 1.0% in 2023, then tumbled by -1476bps to 15.82% in 2024, then surged by 91bps to 1.37% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Return on Equity are 1.37% (Q4 2025), 2.81% (Q3 2025), and 52.03% (Q2 2025).